drugset
drugset / Trial / NCT04328831

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

NCT04328831 ↗

Phase 1 Completed 94 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

Timeline

Start
2020-07-31
Primary completion
2023-08-28
Completion
2023-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI322 Monoclonal antibody — —

Indications

cancer